Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results